Coccidioidomycosis Collaborative Research Centers (P01 Clinical Trial Not Allowed)
This NOFO funds collaborative translational and clinical research centers to support development of a Valley fever (coccidioidomycosis) vaccine; clinical trials are not allowed.
⚑ Clinical trials not allowed. · Foreign organizations and non-domestic components of U.S. organizations are not eligible; foreign components are allowed. · Collaborative, multidisciplinary Center (P01) mechanism.
Unit fits — one characterization, each unit's own rules
| IPPRA | 58 good | portfolio topic: public_health; social/behavioral work is minor; funds applied research; clinical-trial/biomedical core — IPPRA angle is policy/community (capped) |
| Physical Sciences & Engineering (demo) | 55 good | technical depth: minor; funds applied research |
| Tom Love Innovation Hub | 30 weak | funds applied research; deep-tech content |
Description
The purpose of the notice of funding opportunity (NOFO) is to solicit applications for a Coccidioidomycosis Collaborative Research Centers (CCRC) program. This new initiative will establish highly collaborative, multi-disciplinary, research teams to conduct translational and clinical research to support the development of a Valley fever vaccine as outlined in NIAID's Strategic Plan for Research to Develop a Valley fever Vaccine.
Eligibility
Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/International CollaborationsNon-domestic (non-U.S.) Entities (Foreign Organization) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Apply
View on Grants.gov → CONTACT: National Institutes of Health <CoccidioidomycosisResearchCenters@mail.nih.gov>
Proposal brief
Proposal shell · National Institutes of Health conventions
Legacy IPPRA LLM assessment (v2.0, for comparison)
22/100 · gpt-5.4-mini · 2026-07-06
This is a public-health research program focused on Valley fever translational and clinical research, which is relevant to IPPRA only at the margins through health outcomes and crisis-response implications. However, it is predominantly biomedical rather than social/behavioral/policy research, and the NOFO is restricted to U.S. applicants with no obvious role for IPPRA’s core survey, risk-communication, or policy-evaluation strengths.
Legacy scoring history
| 2026-07-06 | 22 | gpt-5.4-mini | This is a public-health research program focused on Valley fever translational and clinical research, which is relevant to IPPRA only at the margins through health outcomes and crisis-response implications. However, it is predominantly biomedical rather than social/behavioral/policy research, and the NOFO is restricted to U.S. applicants with no obvious role for IPPRA’s core survey, risk-communication, or policy-evaluation strengths. |
| 2026-07-06 | 18 | gpt-5.4-mini | This is a biomedical translational/clinical research opportunity focused on Valley fever vaccine development, with little to no direct connection to IPPRA’s core strengths in risk communication, behavior, policy analysis, or community response. A public university could apply as a U.S. domestic institution, but the NOFO is not a meaningful fit for IPPRA’s portfolio and would likely be a technical biomedical role rather than an anchor opportunity. |